Market Intelligence, Clinical Progress, and High-Purity Reagents for NK Cell Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIR3DL1/CD158e drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR3DL1 ECD-Fc / Monomer Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View KIR3DL1 Products |
| Gene Delivery | KIR3DL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines (Flow Cytometry/Reporter Assay validation). |
View KIR3DL1 Products |
| Benchmark Ab | Anti-KIR3DL1 Recombinant Antibody DX9-derived recombinant positive control for binding and blocking assays. |
View KIR3DL1 Products |
| Validator | KIR3DL1 siRNA Set For target knockdown verification in primary NK cells or cell lines. |
View KIR3DL1 Products |
| Related Target A | HLA-B (Bw4) The physiological ligand for KIR3DL1; essential for functional blocking and binding assays. |
View HLA-B Products |
| Related Target B | KIR3DL2 Closest structural homolog (3 Ig domains); critical for selectivity and counter-screening. |
View KIR3DL2 Products |
| Related Target C | CD16a (FCGR3A) Co-target for multi-specific NK cell engagers (NKCEs) to trigger ADCC. |
View CD16a Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allelic Polymorphism Variability | Sequence-verified allotype-specific proteins (e.g., KIR3DL1*001, *015) to guarantee epitope precision. |
| Homolog Counter-Screening (KIR3DL2/KIR2DL) | Full panel of recombinant KIR family proteins strictly verified by mass spectrometry and high-resolution SDS-PAGE. |
| Lack of Validated Controls | Sequence-defined clinical benchmark antibodies (biosimilars) included for assay calibration. |
| Conformational Integrity on Cells | Lentiviral vectors optimized for high-expression stable cell line generation, preserving native membrane folding. |
Live KIR3DL1/CD158e R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIR3DL1/CD158e therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to multi-specific NK cell engagers (NKCEs) and combination therapies. As first-generation checkpoint inhibitors (like PD-1/L1) face resistance, targeting inhibitory receptors on Natural Killer (NK) cells represents the next frontier in oncology. KIR3DL1, which recognizes the Bw4 motif of HLA-A and HLA-B, acts as a critical "off-switch" for NK cells. Blocking this interaction releases NK cell cytotoxicity against MHC-I-deficient or HLA-Bw4-expressing tumor cells, offering a highly synergistic mechanism when combined with tumor-targeting antibodies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Innate Pharma, Bristol Myers Squibb | Solid Tumors, Hematological Malignancies | Blocking Assay (Requires high-purity HLA-Bw4 and KIR3DL1 ECD proteins) |
| NK Cell Engagers (NKCEs) | Sanofi, Affimed, Innate Pharma | Acute Myeloid Leukemia (AML), Lymphoma | Multispecific Binding & ADCC (Requires CD16a and KIR3DL1 target proteins) |
| CAR-NK / Cell Therapy | Academic Institutions, Biotech Startups | Refractory Solid Tumors | Target Validation & Phenotyping (Requires Lentivirus for stable overexpression) |